BMS-1233

• Description:

  BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model[1].

• UNSPSC:

  12352005

• Target:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bms-1233.html

• Smiles:

  N#CC1=CC=CC(COC2=CC(OCC3=CC=CC(C4=CC=CC=C4)=C3C)=C(C=C2CN5CCCCC5C(O)=O)Cl)=C1

• Molecular Formula:

  C35H33ClN2O4

• Molecular Weight:

  581.10

• References & Citations:

  [1]Cheng B, et al., Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment. Signal Transduct Target Ther. 2023 Mar 1;8 (1) :91.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2447065-99-6